Hunkapiller Michael 4

Accession 0001299130-21-000105

CIK 0001299130other

View on SEC.gov Company Profile

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 8:34 PM ET

Size

48.9 KB

Accession

0001299130-21-000105

Insider Transaction Report

Form 4

Period: 2021-02-24

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB

Hunkapiller Michael

Director

Transactions

Exercise/Conversion
Common Stock
2021-02-24$6.14/sh+35,727$219,364→ 884,132 total
Exercise/Conversion
Common Stock
2021-02-24$5.72/sh+90,560$518,003→ 974,692 total
Exercise/Conversion
Common Stock
2021-02-24$7.87/sh+52,766$415,268→ 1,027,458 total
Exercise/Conversion
Common Stock
2021-02-24$5.27/sh+87,374$460,461→ 1,114,832 total
Sale
Common Stock
2021-02-24$35.59/sh−87,349$3,108,402→ 1,027,483 total
Sale
Common Stock
2021-02-24$36.41/sh−55,399$2,017,244→ 972,084 total
Sale
Common Stock
2021-02-24$37.47/sh−72,303$2,708,904→ 899,781 total
Sale
Common Stock
2021-02-24$38.36/sh−51,376$1,970,732→ 848,405 total
Exercise/Conversion
Common Stock
2021-02-25$5.72/sh+67,736$387,450→ 916,141 total
Exercise/Conversion
Common Stock
2021-02-25$7.87/sh+135,882$1,069,391→ 1,052,023 total
Exercise/Conversion
Common Stock
2021-02-25$5.27/sh+135,759$715,450→ 1,187,782 total
Sale
Common Stock
2021-02-25$31.05/sh−110,515$3,430,938→ 1,077,267 total
Sale
Common Stock
2021-02-25$31.97/sh−123,383$3,944,678→ 953,884 total
Sale
Common Stock
2021-02-25$32.88/sh−23,331$767,053→ 930,553 total
Sale
Common Stock
2021-02-25$34.21/sh−49,410$1,690,267→ 881,143 total
Sale
Common Stock
2021-02-25$34.73/sh−29,500$1,024,476→ 851,643 total
Sale
Common Stock
2021-02-25$35.68/sh−3,238$115,532→ 848,405 total
Exercise/Conversion
Stock Option (right to buy)
2021-02-24−35,727→ 0 total
Exercise: $6.14Exp: 2024-03-17→ Common Stock (35,727 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-24−90,560→ 177,485 total
Exercise: $5.72Exp: 2025-03-16→ Common Stock (90,560 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-24−52,766→ 215,245 total
Exercise: $7.87Exp: 2026-03-15→ Common Stock (52,766 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-24−87,374→ 180,893 total
Exercise: $5.27Exp: 2027-02-15→ Common Stock (87,374 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-25−67,736→ 109,749 total
Exercise: $5.72Exp: 2025-03-16→ Common Stock (67,736 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-25−135,882→ 79,363 total
Exercise: $7.87Exp: 2026-03-15→ Common Stock (135,882 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-02-25−135,759→ 45,134 total
Exercise: $5.27Exp: 2027-02-15→ Common Stock (135,759 underlying)

Footnotes (11)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2020.
[F10]This sale price represents the weighted average sale price of the shares sold ranging from $34.53 to $35.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F11]The shares subject to the option are fully vested and exercisable.
[F2]This sale price represents the weighted average sale price of the shares sold ranging from $34.99 to $35.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F3]This sale price represents the weighted average sale price of the shares sold ranging from $35.99 to $36.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F4]This sale price represents the weighted average sale price of the shares sold ranging from $36.99 to $37.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F5]This sale price represents the weighted average sale price of the shares sold ranging from $37.99 to $38.82 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F6]This sale price represents the weighted average sale price of the shares sold ranging from $30.52 to $31.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F7]This sale price represents the weighted average sale price of the shares sold ranging from $31.52 to $32.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F8]This sale price represents the weighted average sale price of the shares sold ranging from $32.52 to $33.51 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
[F9]This sale price represents the weighted average sale price of the shares sold ranging from $33.53 to $34.52 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Documents

1 file

4
certent-form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

CIK 0001299130

→

Entity typeother

Related Parties

filerCIK 0001317102

Filing Metadata

Form type: 4
Filed: Feb 25, 7:00 PM ET
Accepted: Feb 26, 8:34 PM ET
Size: 48.9 KB

View on SEC.gov